Singapore: Taiwan's TaiGen Biotechnology has initiated first burixafor trial for relapsed or refractory acute myeloid le...
Singapore: Bayer's anticoagulant drug, Xarelto (rivaroxaban), has been approved by the China Food and Drug Administratio...
Singapore: Taiwanese company ScinoPharm and US-based Foresee Pharmaceuticals have signed an investment agreement to form...
Singapore: Australian biotechnology company, Novogen's lead candidate product, TRXE-009, has shown a positive result in ...
Singapore: Australian drug delivery technology company, Phosphagenics has achieved succes in its multi-dose oxymorphone ...
Singapore: Australia based Viralytics has initiated a clinical trial to assess its oncolytic virus, Cavatak, in combinat...
Singappore: US Food and Drug Administration (FDA) has granted orphan drug designation to chemotherapy drug candidate Can...
Tokyo: Japan's pharma giant Eisai Co Ltd announced that its European regional headquarters Eisai Europe Ltd has submitte...
Singapore: Baxter has acquired Oncaspar (pegaspargase) product portfolio, a first-line biologic used as part of a multi-...
Singapore: Prana Biotechnology announced the successful completion of Reach2HD, a phase II clinical trial in patients wi...
Singapore: Scientists at A*Star's Singapore Immunology Network (SIgN) have discovered a clue that has the potential to c...
Mumbai: Lupin is setting up a R&D center in the US, and has hired the R&D head of Teva Pharmaceuticals and other...
Singapore: Janssen Pharmaceutical has terminated the research and development alliance with China based Hutchison Mediph...
In 2005, Novartis, a leading healthcare solution provider, decided to partner with The National Center For Genetic Engin...
Asia attracted a lot of interest from foreign multinational giants in the year 2013. This not only led to the increase i...
Singapore: Dengue, also known as break bone fever, is currently the most common vector-borne disease. The World Health ...
Singapore: Novartis received US FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body...
Singapore: Singapore based start-up firm, NMT Pharmaceuticals, has acquired an exclusive worldwide license right to furt...
